Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
1.03
Dollar change
-0.07
Percentage change
-6.36
%
Index- P/E- EPS (ttm)-1.48 Insider Own3.84% Shs Outstand16.95M Perf Week-8.04%
Market Cap17.48M Forward P/E- EPS next Y-0.94 Insider Trans1.56% Shs Float16.32M Perf Month-25.36%
Income-18.40M PEG- EPS next Q-0.28 Inst Own36.60% Short Float0.61% Perf Quarter33.77%
Sales0.65M P/S26.89 EPS this Y26.36% Inst Trans2.78% Short Ratio0.68 Perf Half Y82.30%
Book/sh0.83 P/B1.24 EPS next Y1.05% ROA-30.31% Short Interest0.10M Perf Year48.56%
Cash/sh0.55 P/C1.86 EPS next 5Y- ROE-57.28% 52W Range0.43 - 1.61 Perf YTD40.14%
Dividend Est.- P/FCF- EPS past 5Y39.67% ROI-130.43% 52W High-36.02% Beta0.52
Dividend TTM- Quick Ratio2.56 Sales past 5Y4.54% Gross Margin-22.73% 52W Low142.35% ATR (14)0.09
Dividend Ex-Date- Current Ratio2.56 EPS Y/Y TTM-122.80% Oper. Margin-2594.32% RSI (14)39.64 Volatility6.49% 8.13%
Employees15 Debt/Eq0.00 Sales Y/Y TTM-63.24% Profit Margin-2825.96% Recom1.00 Target Price5.12
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q75.47% Payout0.00% Rel Volume0.55 Prev Close1.10
Sales Surprise0.00% EPS Surprise-25.00% Sales Q/Q11.51% EarningsMar 06 AMC Avg Volume146.88K Price1.03
SMA20-12.04% SMA50-7.77% SMA20014.25% Trades Volume81,350 Change-6.36%
Date Action Analyst Rating Change Price Target Change
Jul-20-20Downgrade Credit Suisse Neutral → Underperform
Nov-11-19Downgrade Credit Suisse Outperform → Neutral $7 → $2
Aug-05-19Resumed Credit Suisse Outperform
Jul-10-19Resumed Credit Suisse Outperform
Apr-24-19Resumed B. Riley FBR Buy $6.50
Feb-15-19Initiated Credit Suisse Outperform $7
Oct-23-18Initiated B. Riley FBR Buy $9
Oct-13-17Reiterated RBC Capital Mkts Outperform $6 → $5
Oct-13-17Downgrade Jefferies Buy → Hold
Jul-14-17Resumed Jefferies Buy $7
Mar-06-24 09:53PM
04:05PM
Mar-01-24 07:30AM
Feb-26-24 04:15PM
Jan-18-24 08:30AM
09:05AM Loading…
Jan-09-24 09:05AM
Dec-12-23 08:30AM
Nov-09-23 11:06AM
Nov-08-23 05:22PM
04:05PM
Nov-07-23 04:05PM
Oct-26-23 04:30PM
Oct-03-23 08:30AM
Sep-12-23 01:02PM
Sep-06-23 08:30AM
05:30PM Loading…
Aug-22-23 05:30PM
Aug-13-23 05:33AM
Aug-11-23 06:07AM
Aug-10-23 05:30PM
04:20PM
04:05PM
Jul-27-23 04:05PM
Jul-21-23 08:00AM
Jul-18-23 08:00AM
May-10-23 06:25PM
05:18PM
04:05PM
May-04-23 10:00AM
May-03-23 10:00AM
Apr-27-23 04:05PM
08:30AM Loading…
Apr-05-23 08:30AM
Apr-04-23 12:30PM
Mar-30-23 06:15PM
04:05PM
Mar-29-23 10:13AM
Mar-21-23 04:05PM
Mar-14-23 08:30AM
Mar-01-23 08:30AM
Dec-29-22 06:02AM
Dec-27-22 08:30AM
Dec-19-22 08:17AM
Dec-08-22 08:30AM
Nov-17-22 05:17AM
Nov-14-22 05:15PM
04:01PM
Nov-03-22 08:30AM
Oct-31-22 08:30AM
Oct-27-22 08:30AM
Oct-26-22 08:30AM
Oct-25-22 04:42PM
08:30AM
Sep-06-22 04:30PM
Aug-25-22 08:30AM
Aug-11-22 05:35PM
04:01PM
08:30AM
Aug-10-22 08:30AM
Jul-28-22 04:50PM
Jul-08-22 06:28AM
May-20-22 12:49PM
May-19-22 11:56AM
08:30AM
May-16-22 08:45AM
07:30AM
May-12-22 05:35PM
May-10-22 05:35PM
08:30AM
May-09-22 07:30PM
Apr-27-22 08:00AM
Apr-25-22 08:30AM
Apr-21-22 08:30AM
Mar-31-22 04:10PM
Mar-29-22 01:08PM
Mar-10-22 05:15PM
04:01PM
Mar-03-22 04:05PM
Feb-01-22 08:30AM
Jan-31-22 04:24AM
Jan-27-22 01:38PM
08:30AM
Jan-12-22 08:30AM
Jan-10-22 08:30AM
Dec-23-21 08:05AM
Dec-15-21 08:30AM
Dec-01-21 07:12PM
Nov-23-21 05:09PM
Nov-15-21 06:45AM
06:00AM
Nov-10-21 08:30AM
Nov-02-21 06:22AM
Oct-28-21 03:06PM
Oct-21-21 09:32PM
Oct-04-21 07:30AM
Sep-10-21 03:19PM
Aug-30-21 05:10PM
08:30AM
Aug-26-21 08:30AM
Aug-19-21 07:07AM
Aug-16-21 05:25PM
04:01PM
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Angotti Vincent J.Chief Executive OfficerDec 13 '23Buy0.7310,0007,268101,805Dec 14 08:11 AM
Angotti Vincent J.Chief Executive OfficerSep 11 '23Buy0.8010,0007,95091,805Sep 11 07:13 PM
Palmer Pamela PChief Medical OfficerAug 25 '23Sale1.097,4428,10430,753Aug 25 04:45 PM
Palmer Pamela PChief Medical OfficerAug 24 '23Sale1.179,51411,13138,195Aug 25 04:45 PM